Compare Stocks → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BSTGNASDAQ:DXRNASDAQ:NMRDNASDAQ:NVNO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTGBiostage$4.45$4.45$4.45▼$4.45$61.78M-1.021,847 shsN/ADXRDaxor$9.55-1.2%$9.02$7.11▼$13.13$45.22M-0.453,394 shs299 shsNMRDNemaura Medical$0.03-11.1%$0.07$0.03▼$1.25$1.26M0.0479,441 shs105,798 shsNVNOenVVeno Medical$5.00+0.6%$5.43$2.51▼$6.97$66.59M1.1107,583 shs75,540 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTGBiostage0.00%0.00%0.00%0.00%-26.08%DXRDaxor-1.33%-1.93%-0.72%+8.85%+966,999,900.00%NMRDNemaura Medical+6.06%-9.09%-57.37%-55.58%-95.27%NVNOenVVeno Medical-2.55%-1.78%-1.78%-2.93%+10.69%“Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTGBiostageN/AN/AN/AN/AN/AN/AN/AN/ADXRDaxorN/AN/AN/AN/AN/AN/AN/AN/ANMRDNemaura Medical2.3486 of 5 stars3.50.00.04.50.01.70.0NVNOenVVeno Medical0.2162 of 5 stars0.01.00.00.02.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTGBiostageN/AN/AN/AN/ADXRDaxorN/AN/AN/AN/ANMRDNemaura Medical3.00Buy$2.507,938.59% UpsideNVNOenVVeno MedicalN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTGBiostageN/AN/AN/AN/A($0.26) per shareN/ADXRDaxor$1.28M35.31N/AN/AN/A∞NMRDNemaura Medical$80K15.69N/AN/A($0.41) per share-0.08NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTGBiostage-$6.07M-$0.58N/A∞N/AN/AN/A-174.43%N/ADXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/ANMRDNemaura Medical-$14.14M-$0.39N/A∞N/AN/AN/A-142.69%N/ANVNOenVVeno Medical-$23.52M-$1.92N/AN/AN/AN/A-70.17%-64.68%7/29/2024 (Estimated)Latest DXR, NVNO, NMRD, and BSTG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024Q1 2024NVNOenVVeno MedicalN/A-$0.31-$0.31-$0.31N/AN/A2/29/2024Q4 2023NVNOenVVeno MedicalN/A-$0.32-$0.32-$0.32N/AN/A2/12/2024Q3 2024NMRDNemaura MedicalN/A-$0.12-$0.12-$0.17N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTGBiostageN/AN/AN/AN/AN/ADXRDaxor$0.030.31%N/AN/AN/ANMRDNemaura MedicalN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTGBiostageN/A2.732.73DXRDaxorN/AN/AN/ANMRDNemaura MedicalN/A0.190.03NVNOenVVeno MedicalN/A34.2234.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTGBiostageN/ADXRDaxor1.34%NMRDNemaura Medical4.41%NVNOenVVeno Medical34.71%Insider OwnershipCompanyInsider OwnershipBSTGBiostage15.30%DXRDaxor60.60%NMRDNemaura Medical41.60%NVNOenVVeno Medical17.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBSTGBiostage713.88 million11.76 millionNot OptionableDXRDaxorN/A4.74 million1.87 millionNot OptionableNMRDNemaura Medical3640.35 million23.57 millionOptionableNVNOenVVeno Medical1913.32 million11.05 millionOptionableDXR, NVNO, NMRD, and BSTG HeadlinesSourceHeadlineNVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024msn.com - May 9 at 12:05 AMenVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 8 at 7:04 PMenVVeno Medical (NASDAQ:NVNO) Trading 0.8% Higher americanbankingnews.com - April 30 at 2:12 AMenVVeno Medical Corporation (NVNO)finance.yahoo.com - April 24 at 5:23 PMenVVeno’s VenoValve SAVVE Trial Topline Efficacy Data Presentedevtoday.com - April 24 at 12:23 PMPositive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposiumfinance.yahoo.com - April 24 at 7:22 AMNew Topline Efficacy Data from the enVVeno Medical…pharmiweb.com - April 16 at 1:05 PMNew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024finance.yahoo.com - April 16 at 1:05 PMenVVeno Medical hires new CCO to guide transitionuk.investing.com - April 11 at 9:42 AMenVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officerfinanznachrichten.de - April 10 at 4:14 AMenVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officerfinance.yahoo.com - April 9 at 12:21 PMenVVeno Medical Corporation (NASDAQ:NVNO) CTO Hamed Alavi Sells 8,334 Sharesinsidertrades.com - March 16 at 10:58 AMNVNO Apr 2024 10.000 callfinance.yahoo.com - March 16 at 2:23 AMenVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunityfinance.yahoo.com - March 15 at 11:16 AMPositive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meetingfinance.yahoo.com - March 6 at 5:49 PMCompanies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growthfinance.yahoo.com - March 3 at 11:28 AMenVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 8:20 PMRecap: enVVeno Medical Q4 Earningsbenzinga.com - February 29 at 8:20 PMenVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 29 at 8:20 PMTopline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024finance.yahoo.com - February 20 at 10:08 AMenVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitabilityfinance.yahoo.com - January 6 at 9:49 AMNVNO Jan 2024 5.000 callca.finance.yahoo.com - December 29 at 4:00 PMenVVeno Medical Corporation: enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposiumfinanznachrichten.de - December 14 at 12:07 PMenVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposiumfinance.yahoo.com - December 14 at 12:07 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiostageOTCMKTS:BSTGBiostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.DaxorNASDAQ:DXRDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.Nemaura MedicalNASDAQ:NMRDNemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.enVVeno MedicalNASDAQ:NVNOenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.